Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer
Cancer,  Clinical Article

Stevenson JP et al. – Combined bevacizumab, pemetrexed, and carboplatin followed by maintenance bevacizumab was well tolerated and displayed remarkable activity in patients with previously untreated, advanced, nonsquamous nonsmall cell lung cancer.

Methods
  • Previously untreated patients with advanced, nonsquamous nonsmall cell lung cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1 received bevacizumab 15mg/kg, pemetrexed 500mg/m2 and carboplatin at an area under the concentration-time curve of 6 intravenously on day 1 every 21days.
  • Responding or stable patients who completed 6 cycles then received bevacizumab maintenance every 21days until disease progression.

Results
  • In total, 43 patients (40 who were evaluable for response) were entered on the study.
  • Treatment-related grade 3/4 toxicities were low and included febrile neutropenia (2%), neutropenia (28%), anemia (18%), thrombocytopenia (11%), hypertension (7%), epistaxis (5%), venous thrombosis (8%), dyspnea (7%), rectovaginal fistula (2.3%), infusion reaction (2%), and cerebrovascular event (2%).
  • One patient died from complications of venous thromboembolism and cerebrovascular accident after Cycle 2.
  • Minimal clinically significant toxicity occurred during maintenance bevacizumab.
  • Two complete responses (5%) were observed, and 17 patients (42%) had a partial response.
  • Fifteen patients (38%) displayed disease stability.
  • The overall disease control rate was 85%.
  • At a median follow-up of 15.8months, the median progression-free survival was 7.1months (95% confidence interval, 5.9-8.3months), and the median overall survival was 17.1months (95% confidence interval, 8.8-25.5months).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close